View : 639 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author남은미*
dc.contributor.author김규보*
dc.date.accessioned2017-12-27T16:31:28Z-
dc.date.available2017-12-27T16:31:28Z-
dc.date.issued2017*
dc.identifier.issn1341-9625*
dc.identifier.otherOAK-20591*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/239487-
dc.description.abstractPurpose: To investigate the significance of carbohydrate antigen 19-9 (CA19-9) levels for survival in locally advanced pancreatic cancer (LAPC) treated with concurrent chemoradiotherapy (CCRT). Methods/patients: We retrospectively reviewed data from 97 LAPC patients treated with CCRT between 2000 and 2013. CA19-9 levels (initial and post-CCRT) and their changes [{(post-CCRT CA19-9 level − initial CA19-9 level)/(initial CA19-9 level)} × 100] were analyzed for overall survival. A cut-off point of 37 U/mL was used to analyze initial and post-CCRT CA19-9 levels. In order to define an optimal cut-off point for change in CA19-9 level, the maxstat package of R was applied. Results: Median overall survival was 14.7 months (95% CI 13.4–16.0), and the 2-year survival rate was 16.5%. The estimated optimal cut-off point of CA19-9 level change was 94.4%. On univariate analyses, CA19-9 level change between initial and post-CCRT was significantly correlated with overall survival (median survival time 9.7 vs 16.3 months, p < 0.001). Multivariate analyses confirmed that CA19-9 level change from initial to post-CCRT was the only prognostic factor (p < 0.001). Conclusions: Change in CA19-9 level between initial and post-CCRT was a significant prognostic marker for overall survival in LAPC treated with CCRT. A CA19-9 level increase >94.4% might serve as a surrogate marker for poor survival in patients with LAPC undergoing CCRT, and the prognostic power surpassed other CA19-9 variables including initial and post-CCRT values. © 2017, Japan Society of Clinical Oncology.*
dc.languageEnglish*
dc.publisherSpringer Tokyo*
dc.subjectCA19-9*
dc.subjectConcurrent chemoradiotherapy*
dc.subjectLocally advanced pancreatic cancer*
dc.titleChange in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy*
dc.typeArticle*
dc.relation.issue6*
dc.relation.volume22*
dc.relation.indexSCIE*
dc.relation.indexSCOPUS*
dc.relation.startpage1069*
dc.relation.lastpage1075*
dc.relation.journaltitleInternational Journal of Clinical Oncology*
dc.identifier.doi10.1007/s10147-017-1129-7*
dc.identifier.wosidWOS:000414780900011*
dc.identifier.scopusid2-s2.0-85018770563*
dc.author.googleKim Y.-J.*
dc.author.googleKoh H.K.*
dc.author.googleChie E.K.*
dc.author.googleOh D.-Y.*
dc.author.googleBang Y.-J.*
dc.author.googleNam E.M.*
dc.author.googleKim K.*
dc.contributor.scopusid남은미(7005824288;57226666155)*
dc.contributor.scopusid김규보(8213302900)*
dc.date.modifydate20240301081003*
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE